LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities...
Related Questions
How likely is the lawsuit to result in a material settlement or judgment that could affect REPL's financials?
What is the expected short‑term volatility and potential price swing for REPL following this negative news?
Are there any precedent cases involving similar securities fraud claims that impacted the stock price of comparable biotech firms?